Drug Trial Radar · NCT02799602
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,306
Actual
Start
Nov 30, 2016
Primary completion
Oct 25, 2021
Study completion Apr 11, 2023
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Jun 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
Conditions
- Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201)Drug
600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
Standard ADT (androgen deprivation therapy)Drug
As prescribed by the treating physician.
DocetaxelDrug
As prescribed by the treating physician.
PlaceboDrug
Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- OS From Date of Randomization Until Death From Any Cause - Number of EventsTime frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)
- OS From Date of Randomization Until Death From Any Cause - MonthTime frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)
Locations
322 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Chandler, Arizona
Site not named
Tucson, Arizona
Site not named
Beverly Hills, California
Site not named
Duarte, California
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Gainesville, Florida
Site not named
Miami Beach, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Peoria, Illinois
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Towson, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Billings, Montana
Site not named
Omaha, Nebraska
Site not named
Lebanon, New Hampshire
Site not named
Camden, New Jersey
Site not named
Englewood, New Jersey
Site not named
Hackensack, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Poughkeepsie, New York
Site not named
Rochester, New York
Site not named
The Bronx, New York
Site not named
Concord, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Gahanna, Ohio
Showing 40 of 322 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.